AMN107 drug shows promise in leukemia resistance to Gleevec The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D read more here . Anderson Cancer Center. At the 47th Annual Interacting with of the American Culture of Hematology , the investigators reported marked improvement in result in all three phases of chronic myeloid leukemia in addition to advantage in treating a form of acute lymphocytic leukemia that shares the same genetic abnormality as CML, the Philadelphia chromosome.
Quinet, MD, FACP, Ochsner Health Program Rami Rihani, PharmD, Advocate Medical Group ‘In today's health care environment, quality outcomes in specialty caution, including rheumatology, will increasingly affect provider organizations' bottom line,’ said Donald W. Fisher, Ph.D., CAE, president and ceo of the American Medical Group Association and secretary of the board of AMGF. ‘Participation in the AMGF GUIDELINES RA Collaborative gives participants mission-critical knowledge in engaging specialty departments such as for example rheumatology in efficiency measurement and improvement.’ This program gives a shared learning environment where participants can exchange strategies and encounters as they work to boost the care provided to patients with RA.